Carcinoembryonic antigen and cancer: a comparative study.

Area of Science:

• Oncology
• Immunochemistry
• Clinical Diagnostics

Background:

• Carcinoembryonic antigen (CEA) is a biomarker investigated for cancer detection.
• Radioimmunoassay (RIA) is a common method for quantifying biomarkers like CEA.
• Variations in CEA assay kits may impact diagnostic accuracy and clinical utility.

Purpose of the Study:

• To evaluate and compare the performance of three different radioimmunoassay kits for carcinoembryonic antigen (CEA).
• To assess the clinical usefulness, reproducibility, and procedural advantages of each CEA assay kit.
• To determine the diagnostic and prognostic value of CEA in patients with malignant and non-malignant diseases.

Main Methods:

• Radioimmunoassay (RIA) of sera from 212 patients with various diseases.
• Utilized three distinct CEA assay kits: Hoffman La Roche (RCK), Sorin-IRE (SCK), and Istituto Sieroterapico Milanese (ICK).
• Compared assay results based on carcinoma type, focusing on endodermally-derived system carcinomas and others.

Main Results:

• The RCK kit showed higher positivity (72.6%) for endodermally-derived system carcinomas compared to SCK (63.1%) and ICK (56.2%).
• For other carcinomas, ICK (50.0%) and SCK (47.1%) yielded better results than RCK (30.6%).
• The double antibody method (SCK, ICK) was found clinically more advantageous than the RCK method.

Conclusions:

• The CEA assay is not suitable for diagnosing gastrointestinal cancers.
• CEA levels are clinically useful as a measure of "cancerosity" for prognostic purposes.
• The double antibody method offers greater clinical utility compared to the RCK kit's method.